De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Apellis Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Apellis Pharmaceuticals' is Cedric Francois, benoemd in Sep2009, heeft een ambtstermijn van 15.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.37M, bestaande uit 7.1% salaris en 92.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.51% van de aandelen van het bedrijf, ter waarde $ 52.90M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.7 jaar en 9.3 jaar.

Belangrijke informatie

Cedric Francois

Algemeen directeur

US$10.4m

Totale compensatie

Percentage CEO-salaris	7.1%
Dienstverband CEO	15.1yrs
Eigendom CEO	1.5%
Management gemiddelde ambtstermijn	5.7yrs
Gemiddelde ambtstermijn bestuur	9.3yrs

Recente managementupdates

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Recent updates

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Jul 12

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Jul 19

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

May 13

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Apr 18

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?

Dec 14

Some Analysts Just Cut Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates

Nov 09

Analyse CEO-vergoeding

Hoe is Cedric Francois's beloning veranderd ten opzichte van Apellis Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$333m
Mar 31 2024	n/a	n/a	-US$417m
Dec 31 2023	US$10m	US$735k	-US$529m
Sep 30 2023	n/a	n/a	-US$606m
Jun 30 2023	n/a	n/a	-US$657m
Mar 31 2023	n/a	n/a	-US$691m
Dec 31 2022	US$9m	US$681k	-US$652m
Sep 30 2022	n/a	n/a	-US$634m
Jun 30 2022	n/a	n/a	-US$638m
Mar 31 2022	n/a	n/a	-US$702m
Dec 31 2021	US$9m	US$647k	-US$746m
Sep 30 2021	n/a	n/a	-US$520m
Jun 30 2021	n/a	n/a	-US$460m
Mar 31 2021	n/a	n/a	-US$360m
Dec 31 2020	US$9m	US$619k	-US$345m
Sep 30 2020	n/a	n/a	-US$536m
Jun 30 2020	n/a	n/a	-US$470m
Mar 31 2020	n/a	n/a	-US$423m
Dec 31 2019	US$4m	US$560k	-US$305m
Sep 30 2019	n/a	n/a	-US$228m
Jun 30 2019	n/a	n/a	-US$194m
Mar 31 2019	n/a	n/a	-US$156m
Dec 31 2018	US$4m	US$550k	-US$128m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$85m
Mar 31 2018	n/a	n/a	-US$64m
Dec 31 2017	US$2m	US$400k	-US$51m

Compensatie versus markt: De totale vergoeding ($USD 10.37M ) Cedric } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).

Compensatie versus inkomsten: De vergoeding van Cedric is gestegen terwijl het bedrijf verliesgevend is.

CEO

Cedric Francois (52 yo)

15.1yrs

Tenure

US$10,373,049

Compensatie

Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Cedric Francois	Co-Founder	15.1yrs	US$10.37m	1.51% $ 50.9m
Alec Machiels	Co-Founder & Director	15.8yrs	US$495.96k	0.64% $ 21.5m
Timothy Sullivan	CFO & Treasurer	7yrs	US$3.74m	0.084% $ 2.8m
Adam Townsend	Chief Operating Officer	less than a year	US$3.71m	0.023% $ 783.6k
David Watson	General Counsel	10.8yrs	US$4.89m	0.094% $ 3.2m
Caroline Baumal	Chief Medical Officer	1.8yrs	US$4.43m	0.0052% $ 174.0k
Pascal Deschatelets	Co-Founder & Chief Scientific Officer	15.1yrs	US$3.08m	0.91% $ 30.9m
James Chopas	VP, Corporate Controller & Chief Accounting Officer	3.2yrs	geen gegevens	0.010% $ 336.1k
Meredith Kaya	Senior Vice President	no data	geen gegevens	geen gegevens
Karen Lewis	Chief People Officer	4.4yrs	geen gegevens	0.00073% $ 24.7k
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens
Victoria Brown	Senior Vice President	5.7yrs	geen gegevens	0.0031% $ 104.4k

5.7yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van APLS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Cedric Francois	Co-Founder	15.1yrs	US$10.37m	1.51% $ 50.9m
Alec Machiels	Co-Founder & Director	15.1yrs	US$495.96k	0.64% $ 21.5m
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Lokchung L. Chan	Independent Chairman of the Board	11.3yrs	US$504.08k	0.00056% $ 18.9k
Stephanie O'Brien	Independent Director	11.3yrs	US$488.46k	0.00056% $ 18.9k
Gabriel Coscas	Member of AMD Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Robert Brodsky	Member of PNH Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Michael Yeadon	Member of Pulmonology Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Paul Fonteyne	Independent Director	4.5yrs	US$489.08k	0.0047% $ 157.4k
A. Dunlop	Independent Director	14.6yrs	US$480.96k	0.12% $ 4.0m
Marsha Wills-Karp	Member of Pulmonology Scientific Advisory Board	no data	geen gegevens	geen gegevens
Carl Atkinson	Member of Pulmonology Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens

9.3yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van APLS wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.3 jaar).

Apellis Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Independent Director notifies of intention to sell stock

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Recent updates

Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion

Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Price target decreased by 7.6% to US$69.12

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 11%

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Independent Director notifies of intention to sell stock

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Consensus EPS estimates fall by 17%

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 18%

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Consensus EPS estimates upgraded to US$0.98 loss

Consensus EPS estimates upgraded to US$1.00 loss

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Technical Operations Officer recently sold US$646k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Co-Founder notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold US$525k worth of stock

Price target increased by 9.0% to US$71.44

Price target decreased by 9.6% to US$66.69

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

CFO & Treasurer exercised options and sold US$633k worth of stock

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Price target decreased by 9.8% to US$93.23

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

New minor risk - Share price stability

General Counsel notifies of intention to sell stock

Chief People Officer notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

Consensus revenue estimates increase by 57%, EPS downgraded

Price target increased by 12% to US$100

Chief Commercial Officer notifies of intention to sell stock

Insufficient new directors

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Chief Commercial Officer notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock